Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes

Journal:

Cell Stem Cell

Published:

2025-09-16

DOI:

10.1016/j.stem.2025.08.012

Affiliations:

6

Authors:

16

Go to article

Institutions	Authors	Share
Luxa Biotechnology, United States of America (USA)	5.000000	0.31
Kellogg Eye Center, U-M, United States of America (USA)	4.000000	0.25
Neural Stem Cell Institute (NSCI), United States of America (USA)	3.000000	0.19
Cedars-Sinai Medical Center (Cedars-Sinai), United States of America (USA)	2.000000	0.13
The Emmes Company, United States of America (USA)	2.000000	0.13

Interested in Ophthalmology and Optometry?